Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Ascending)
59676-0030-56 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-84 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59572-0720-12 59572-0720 Fedratinib Hydrochloride Inrebic 100.0 mg/1 Chemotherapy Enzyme Inhibitor JAK2, FLT3 Oral Aug. 16, 2019 In Use
68727-0712-01 68727-0712 Lurbinectedin ZEPZELCA 0.5 mg/mL Chemotherapy Alkylating Agent Adduct Forming Agent Intravenous June 15, 2020 In Use
50242-0105-01 50242-0105 polatuzumab vedotin POLIVY 140.0 mg/7.52mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous June 10, 2019 In Use
50881-0026-01 50881-0026 Pemigatinib PEMAZYRE 4.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral April 17, 2020 In Use
50881-0027-01 50881-0027 Pemigatinib PEMAZYRE 9.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral April 17, 2020 In Use
50881-0028-01 50881-0028 Pemigatinib PEMAZYRE 13.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral April 17, 2020 In Use
55135-0132-01 55135-0132 SACITUZUMAB GOVITECAN TRODELVY 180.0 mg/1 Immunotherapy Drug Antibody Conjugate Trop-2 Intravenous April 23, 2020 In Use
59572-0711-01 59572-0711 Luspatercept REBLOZYL 25.0 mg/1 Ancillary Therapy Erythropoiesis-Stimulating Agent Subcutaneous Nov. 8, 2019 In Use
59572-0775-01 59572-0775 Luspatercept Reblozyl 75.0 mg/1 Immunotherapy Erythropoiesis-Stimulating Agent Subcutaneous Nov. 8, 2019 In Use
72607-0100-00 72607-0100 tazemetostat TAZVERIK 200.0 mg/1 Chemotherapy Enzyme Inhibitor EZH2 Oral Jan. 23, 2020 In Use
73535-0208-01 73535-0208 Tafasitamab-cxix MONJUVI 200.0 mg/5mL Immunotherapy Monoclonal Antibody CD19 Intravenous Aug. 5, 2020 In Use
00069-0305-01 00069-0305 Trastuzumab-qyyp Trazimera 420.0 mg/20 mL Immunotherapy Monoclonal Antibody HER2 Intravenous Feb. 24, 2020 In Use
55513-0132-01 55513-0132 trastuzumab-anns Kanjinti 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous June 11, 2019 In Use
00069-0284-03 00069-0284 Palbociclib Ibrance 75.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
65162-0240-03 65162-0240 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Dec. 29, 2018 In Use
00054-9817-25 00054-9817 PredniSONE PredniSONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00054-9817-29 00054-9817 PredniSONE PredniSONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00054-9818-25 00054-9818 PredniSONE PredniSONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00054-9818-29 00054-9818 PredniSONE PredniSONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00054-9828-25 00054-9828 PredniSONE PredniSONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00054-9828-31 00054-9828 PredniSONE PredniSONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00069-1198-30 00069-1198 dacomitinib Vizimpro 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 4, 2018 In Use
00378-0014-01 00378-0014 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 18, 1992 In Use
00555-0572-02 00555-0572 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Nov. 1, 1990 In Use
00555-0572-35 00555-0572 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Nov. 1, 1990 In Use
00143-9830-01 00143-9830 Methotrexate Methotrexate 1.0 g/1 Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous April 25, 2017 In Use
00703-4239-01 00703-4239 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 23, 2014 In Use
00703-4239-81 00703-4239 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 19, 2016 In Use
00703-4244-01 00703-4244 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 4, 2006 In Use
00703-4244-81 00703-4244 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 15, 2016 In Use
00703-4246-01 00703-4246 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 1, 2006 In Use
00703-4246-81 00703-4246 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Nov. 25, 2015 In Use
57277-0105-05 57277-0105 carboplatin Injection Carboplatin 50.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
57277-0106-15 57277-0106 carboplatin Injection Carboplatin 150.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
00078-0681-66 00078-0681 Dabrafenib Tafinlar 75.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral April 1, 2016 In Use
00078-0682-66 00078-0682 Dabrafenib Tafinlar 50.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral April 12, 2016 In Use
00069-3030-20 00069-3030 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 23, 1987 In Use
00069-3034-20 00069-3034 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 23, 1987 In Use
00310-0482-30 00310-0482 Gefitinib IRESSA 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 13, 2015 In Use
00310-0482-93 00310-0482 Gefitinib IRESSA 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 25, 2016 Aug. 31, 2019 In Use
00409-0181-01 00409-0181 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 26, 2011 In Use
00409-0181-25 00409-0181 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 9, 2013 In Use
00409-0182-01 00409-0182 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 22, 2011 In Use
00409-0182-25 00409-0182 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 29, 2013 In Use
00409-0183-01 00409-0183 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 24, 2011 In Use
00409-0183-25 00409-0183 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 9, 2013 In Use
00409-0185-01 00409-0185 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 26, 2011 In Use
00409-0187-01 00409-0187 GEMCITABINE GEMCITABINE 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Nov. 15, 2010 In Use

Found 10,000 results in 2 millisecondsExport these results